As MAPK-signaling reactivation upon KIT/PDGFRA inhibition decreases imatinib anti-tumoral effect [23], we asked whether silencing LIX1 in GIST-T1 cell lines exposed to imatinib may overcome this effect. This evidence concerns the gene KIT and gastrointestinal stromal tumor.